We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Medipan to Distribute Pronostics' Autoimmune Diagnostics in Germany and Austria

By HospiMedica staff writers
Posted on 17 Mar 2008
Pronostics Ltd. More...
(Cambridge, UK), a developer and manufacturer of next-generation multiplexed diagnostics, has signed a distribution agreement with Medipan GmbH (Berlin, Germany) for its autoimmune disease biomarker assays. Medipan, which distributes in vitro diagnostic tests in the field of autoimmunity, will have an exclusive license to sell Pronostics' UltraPlex ANA, coeliac, and thyroid assays in Germany and Austria.

Germany is Europe's largest market for diagnostic products. As part of the agreement, Medipan will market the assays to hospitals and large private laboratories. The deal could initially generate up to US$3.1 million (€2 million) in revenues.

UltraPlex assays provide a powerful tool for rapid, accurate, and inexpensive diagnosis of autoimmune diseases. UltraPlex is a highly accurate, digital multiplexing solution that enables tens to hundreds of tests to be performed simultaneously in a single assay using a microscopic bar-coding system. Pronostics lead product, the UltraPlex ANA assay, which consists of 11 tests in one, provides valuable time and cost savings compared to existing serial testing approaches using panels of human epithelial type 2 cell (Hep-2) screens and enzyme-linked immunosorbant assays (ELISAs). It allows hospitals and laboratories to perform fully automated profiles of patient samples and gives both quantitative and qualitative results for antibodies to autoimmune diseases.

Dr Dirk Roggenbuck, CEO of Medipan, said: "We are very pleased to have been chosen as the distributor for the UltraPlex range of autoimmune assays. The UltraPlex platform is more efficient and economical in the diagnosis of autoimmune diseases than conventional approaches, and we are looking forward to providing our customers with this improved service.”

Medipan develops and distributes in-vitro diagnostic tests, predominantly in the field of autoimmunity. Medipan's product portfolio provides a wide range of assays and it is expanding continuously. The company offers technical, medical, and scientific expertise and support ensuring the success of their partner's clinical and business objectives.


Related Links:
Pronostics
Medipan

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.